Endothelial dysfunction in COVID-19: Current findings and therapeutic implications

Area of Science:

• Cardiovascular Medicine
• Infectious Diseases
• Vascular Biology

Background:

• Coronavirus disease 2019 (COVID-19) is linked to non-pulmonary complications like heart injury, kidney failure, and thromboembolism.
• Endothelial dysfunction is a potential unifying mechanism underlying these severe COVID-19 complications.

Purpose of the Study:

• To review the association between endothelial dysfunction and COVID-19.
• To explore the therapeutic implications of addressing endothelial dysfunction in COVID-19 patients.

Main Methods:

• Literature review of studies on COVID-19, endothelial function, and related comorbidities.
• Analysis of preliminary data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of endothelial cells.
• Examination of evidence for endothelial injury and inflammation in severe COVID-19.

Main Results:

• Endothelial dysfunction is prevalent in COVID-19 and associated comorbidities (hypertension, diabetes, obesity).
• SARS-CoV-2 may infect vascular endothelial cells, causing widespread injury and inflammation.
• Impaired endothelial function in COVID-19 can lead to poor organ perfusion and thrombotic events.

Conclusions:

• Addressing endothelial dysfunction is a potential therapeutic strategy for improving COVID-19 outcomes.
• ACE inhibitors, ARBs, and statins may offer benefits by improving endothelial function.
• Ongoing clinical trials are investigating therapies targeting endothelial dysfunction in COVID-19.